Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

By E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J. Canon, J. Van Laethem, J. Maurel, G. Richardson and 2 more. Journal of Clinical Oncology, 2007

1,956 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/c90a078cdebcd9284d1300d6b14520e9a07c2b7b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Carlos L. Arteaga
2. J. Engelman

Citations in the corpus

• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. (2008, background): “Biologics targeting the epidermal growth factor receptor (EGFR) are effective in disease refractory to FU, irinotecan, and oxaliplatin.(12,13) Cetuximab (ERBITUX; ImClone Systems Inc, New York, NY, and Bristol-Myers Squibb Co, Princeton, NJ), a chimeric monoclonal immunoglobulin 1 that binds to the ”
• ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, result): “Despite this difference, phase III studies have demonstrated clinical efficacy similar to that of cetuximab (Douillard et al., 2014; Jonker et al., 2007; Van Cutsem et al., 2007, 2009).”